GlucoTrack to Showcase CBGM at Diabetes Meeting

The latest announcement is out from GlucoTrack ( (GCTK) ).

On July 31, 2025, Glucotrack, Inc. announced its participation in the 2025 Association of Diabetes Care and Education Specialists Annual Meeting, scheduled for August 8-11 in Phoenix, AZ. The company will showcase its Continuous Blood Glucose Monitor (CBGM) and present a poster on endocrinologists’ perspectives on this implantable technology. The CBGM offers a long-term, implantable solution for diabetes management, providing real-time glucose readings directly from the blood without the need for on-body wearables, addressing limitations of current CGM technology.

Spark’s Take on GCTK Stock

According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.

GlucoTrack’s overall stock score is significantly impacted by its poor financial performance, characterized by a lack of revenue and negative equity. However, positive corporate events, including strategic partnerships and clinical advancements, provide some optimism. The technical analysis and valuation further emphasize the company’s current challenges, with bearish trends and poor valuation metrics. While speculative interest might arise from recent developments, the stock remains under pressure due to financial instability.

To see Spark’s full report on GCTK stock, click here.

More about GlucoTrack

Glucotrack, Inc. is a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system.

Average Trading Volume: 932,905

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.73M

For an in-depth examination of GCTK stock, go to TipRanks’ Overview page.